Expressing support for the designation of September 2025 as National Polycystic Kidney Disease Awareness Month, and raising awareness and understanding of polycystic kidney disease.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, Expressing support for the designation of September 2025 as National Polycystic Kidney Disease Awareness Month, and raising awareness and understanding of polycystic kidney disease., changes federal law or congressional policy affecting transportation operators and travelers. The main policy domain is Transportation, Science & Space.
Who Benefits and How
transportation operators and travelers may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies, transportation operators and travelers may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section HB80FC465FC3D40D1BE1E187623E6696C: That the House of Representatives— expresses support for the designation of National Polycystic Kidney Disease Awareness Month; supports the goals and ideals...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
This bill, Expressing support for the designation of September 2025 as National Polycystic Kidney Disease Awareness Month, and raising awareness and understanding of polycystic kidney disease., changes federal law or congressional policy affecting transportation operators and travelers.
Key Policy Areas
Transportation, Science & Space
Primary Purpose
This bill, Expressing support for the designation of September 2025 as National Polycystic Kidney Disease Awareness Month, and raising awareness and understanding of polycystic kidney disease., changes federal law or congressional policy affecting transportation operators and travelers.
Policy Domains
Whole bill
Identified Gains
- transportation operators and travelers
Identified Costs
- federal implementing agencies
- transportation operators and travelers
Sponsors
Legislative Progress
In CommitteeMr. Cleaver (for himself and Mr. Graves) submitted the following …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "federal_implementing_agencies"
- → Federal agencies assigned duties by the bill
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology